Barclays Raises Replimune Group (NASDAQ:REPL) Price Target to $50.00

Replimune Group (NASDAQ:REPL) had its price objective raised by Barclays from $29.00 to $50.00 in a report published on Thursday, The Fly reports. They currently have an overweight rating on the stock.

Several other brokerages have also issued reports on REPL. Chardan Capital lifted their price target on Replimune Group from $30.00 to $48.00 and gave the company a buy rating in a report on Wednesday. BidaskClub upgraded Replimune Group from a sell rating to a hold rating in a report on Tuesday, September 1st. HC Wainwright upgraded Replimune Group from a neutral rating to a buy rating and boosted their target price for the stock from $25.00 to $54.00 in a report on Thursday. Zacks Investment Research upgraded Replimune Group from a sell rating to a hold rating in a report on Saturday, October 10th. Finally, SVB Leerink boosted their target price on Replimune Group from $27.00 to $44.00 and gave the stock an outperform rating in a report on Thursday. Three investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. Replimune Group currently has an average rating of Buy and a consensus price target of $42.06.

Shares of Replimune Group stock opened at $40.98 on Thursday. The firm has a market cap of $1.65 billion, a price-to-earnings ratio of -24.69 and a beta of 3.20. The company has a debt-to-equity ratio of 0.14, a current ratio of 22.54 and a quick ratio of 22.54. Replimune Group has a 52-week low of $8.58 and a 52-week high of $46.30. The stock has a 50-day simple moving average of $24.54 and a 200-day simple moving average of $20.54.

Replimune Group (NASDAQ:REPL) last announced its quarterly earnings results on Friday, August 7th. The company reported ($0.44) earnings per share (EPS) for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.44). As a group, equities research analysts predict that Replimune Group will post -1.78 earnings per share for the current year.

In other Replimune Group news, COO Colin Love sold 15,000 shares of Replimune Group stock in a transaction that occurred on Monday, August 17th. The stock was sold at an average price of $23.44, for a total value of $351,600.00. Following the transaction, the chief operating officer now directly owns 1,042,488 shares of the company’s stock, valued at approximately $24,435,918.72. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, insider Pamela Esposito sold 5,000 shares of Replimune Group stock in a transaction that occurred on Monday, August 31st. The stock was sold at an average price of $27.05, for a total value of $135,250.00. Following the completion of the transaction, the insider now directly owns 117,700 shares in the company, valued at $3,183,785. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 36,000 shares of company stock worth $1,013,250. Company insiders own 50.90% of the company’s stock.

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Nuveen Asset Management LLC increased its position in shares of Replimune Group by 24.7% during the second quarter. Nuveen Asset Management LLC now owns 206,392 shares of the company’s stock valued at $5,129,000 after purchasing an additional 40,871 shares during the period. FMR LLC increased its position in shares of Replimune Group by 26.7% during the second quarter. FMR LLC now owns 1,127,619 shares of the company’s stock valued at $28,021,000 after purchasing an additional 237,859 shares during the period. Charles Schwab Investment Management Inc. increased its position in shares of Replimune Group by 25.4% during the second quarter. Charles Schwab Investment Management Inc. now owns 40,758 shares of the company’s stock valued at $1,013,000 after purchasing an additional 8,264 shares during the period. Great West Life Assurance Co. Can bought a new stake in shares of Replimune Group during the second quarter valued at approximately $42,000. Finally, Omega Fund Management LLC increased its position in shares of Replimune Group by 0.4% during the second quarter. Omega Fund Management LLC now owns 5,344,971 shares of the company’s stock valued at $132,161,000 after purchasing an additional 21,516 shares during the period. Institutional investors and hedge funds own 60.86% of the company’s stock.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company uses its proprietary Immulytic platform to design and develop product candidates that are intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1 that is in Phase I/II clinical trials for a range of solid tumors.

Further Reading: The benefits and drawbacks of dollar cost averaging

The Fly

Analyst Recommendations for Replimune Group (NASDAQ:REPL)

Receive News & Ratings for Replimune Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Replimune Group and related companies with MarketBeat.com's FREE daily email newsletter.